100 Binney Street
About Foghorn Therapeutics
A Flagship Pioneering company, Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.
By manipulating this system with our unique Gene Traffic ControlTM Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.
With the Gene Traffic ControlTM Platform, Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
10 articles with Foghorn Therapeutics
10/28/2020Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share
10/23/2020Foghorn Therapeutics hits the Nasdaq offering 7.5 million shares at $16 apiece.
Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target
Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada.
Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.
Krystal Biotech and Foghorn Therapeutics are beginning 2020 with significant expansion projects.
Samuel Agresta appointed Chief Medical Officer; Allan Reine to serve as Chief Financial Officer
Foghorn® Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on insights into genetic mutations in the chromatin regulatory system, and Flagship Pioneering, a unique life science innovation enterprise, today announced the appointment of Carl P. Decicco, Ph.D., as Foghorn’s new chief scientific officer (CSO
Foghorn Therapeutics has officially launched with a $50 million investment and the ambitious goal of altering the way our genes work.
Company's Proprietary Gene Traffic Control™ product platform provides a new way to think about treating disease.